•   
  •   
  •   

Classics CureVac reduces production network for Covid-19 vaccine

16:55  14 september  2021
16:55  14 september  2021 Source:   ksta.de

GM amping up EV and autonomous vehicle development to $35B through 2025

  GM amping up EV and autonomous vehicle development to $35B through 2025 General Motors is accelerating investments in EVs and AVs, and has announced two more Ultium battery plans in North America."GM is also announcing two new Ultium battery cell plants in the US, in addition to our plants that are already under construction in Ohio and Tennessee," GM's CEO Mary Barra said in a statement on LinkedIn. The automaker did not disclose where those plants will be located.

The biotech company CureVac reduces the production network due to lower demand for its Corona vaccine. The contracts with Wacker Chemie and Celonic would be terminated, shared the company in Tübingen.

Das Curevac-Präparat hat eine Wirksamkeit von 48 Prozent gegen eine Covid-19-Erkrankung über alle Altersgruppen hinweg. © Sebastian Gollnow / dpa The CureVac preparation has an efficacy of 48 percent against a Covid-19 disease across all age groups.

The decision is a response to the lower short-term peak demand for vaccines following the first wave of pandemic sanctuary, it was said. This has led to a further "changed demand" according to Curevacs Covid-19 vaccine candidates of the first generation (CVNCOV). This is currently reviewed by the European Drug Authority (EMA).

The US sent 2.5 million COVID-19 vaccines to Taiwan - more than triple it initially pledged - as it deals with an unexpected outbreak

  The US sent 2.5 million COVID-19 vaccines to Taiwan - more than triple it initially pledged - as it deals with an unexpected outbreak Harley-Davidson is on a mission to boost sales by streamlining its motorcycle offerings, limiting production, focusing on fewer markets, and standing up its LiveWire line as an independent brand in a big bet on EVs. We'll get the roadmap from the CEO.

EMA approval further open

Whether the EMA is allowed the vaccine is further open. At the end of June, CureVac announced that the effectiveness of his vaccine candidate CVNCOV was lower than the other vaccines. The Tübingen biotech company was assumed at the beginning of July that EMA will allow the vaccine to allow despite low efficacy. According to a final analysis, the CureVac preparation had shown an efficacy of 48 percent against a Covid-19 disease across all age groups.

Financial details of the consequences of the terminated production partnerships did not call CureVac. The contracts with Rentschler Biopharma and Novartis remained. CVNCOV will continue to be examined by the European Drug Authority, it continued. In the fourth quarter, a study on CV2COV should also begin, a second-generation Covid-19 vaccine candidates developed together with GlaxosmithKline.

Vaccine Sputnik V: WHO finds problems on a site, Russia says that it is regulated

 Vaccine Sputnik V: WHO finds problems on a site, Russia says that it is regulated the WHO was concerned with a possible lack of traceability inspection - WHO was concerned with 'A possible lack of traceability not touches my vaccine. While inspectors of the World Health Organization (WHO) had pointed on Wednesdays on one of the Russian Sputnik V vaccine production sites, the Kremlin assured that everything had been solved since.

The Federal Government originally planned the CureVac vaccine for the vaccination campaign. CureVac also involves the federal government to 16 percent indirectly via the State Bank KfW. In this way, politics wanted to secure the company against a possible takeover from abroad. The largest share of the company holds the SAP co-founder and Investor Dietmar Hopp. The preparation of the Tübing company is a so-called mRNA vaccine - such as the BionTech / Pfizer (Germany / USA) and Moderna (USA).

On Wacker Chemie, the termination of the contract has no major impact, the Munich Group announced. For the Wacker Biosolutions division, this has no significant impact on sales and earnings development. WACKER wants to use the releasing capacities of its Dutch vaccine production for other customers.

BionTech vaccine for five to eleven-year-olds safe and effective .
Mainz. Now everything should go completely: BIONTECH and PFIZER want to apply for the approval of their Corona vaccine for five to eleven-year children as quickly as possible. The vaccine has proven to be safe and effective in studies. © Arne Dedert The logo of the biotechnology company BIONTECH (symbol image). This shared the two pharmaceutical companies on Monday in Mainz after evaluating the first results of the admission study for the comrairy for under twelve-year-old.

usr: 0
This is interesting!